BACKGROUND: The use of nonprescription and herbal products by the public is rising,
resulting in an increased potential for adverse reactions or drug interactions in cardiac patients. …

OBJECTIVE: To characterize national and regional patterns of antimicrobial prophylaxis in
adult cardiac surgery across Canada. DESIGN: Retrospective, cross-sectional analysis. …

… Fran Paradiso-Hardy participated in a panel discussion on the role of clopidogrel and
chaired and presented at an advisory board meeting related to clopodigrel. Eric Cohen has …

… Address reprint requests to Fran L. Paradiso-Hardy, M.Sc., FCSHP, Sunnybrook and
Women’s College Health Sciences Centre, 2075 Bayview Avenue, Room E300, Toronto, ON, …

Thrombocytopenia following eptifibatide therapy is a rare event, and acute severe
thrombocytopenia following readministration has not been reported. We describe a case of acute …

Limited data are available with regard to the pharmacodynamics and safety of combining
enoxaparin with glycoprotein IIb/IIIa inhibition during elective percutaneous coronary …

ABSTRACT Objectives: To determine the direct costs involved in the administration of intravenous
(IV) unfractionated heparin (UFH) compared with the projected costs of subcutaneous (…

Objectives To perform a comprehensive causality assessment of the 11 published cases of
TTP to assess quantitatively the extent to which clopidogrel was the causative factor. …

… There were four (1.3%) cases of acute thrombocytopenia (platelet count less than 100 x
10(9)/L) among 305 patients reviewed. One patient had been previously exposed to eptifibatide. …

Clopidogrel is appropriate as a replacement for ticlopidine when used in combination with
acetylsalicylic acid in the setting of percutaneous coronary intervention (PCI). Compared with …